In a nutshell
This study investigated the safety and effectiveness of alirocumab (Praluent) and evolocumab (Repatha) in the treatment of coronary artery disease (CAD).
They found that these drugs are associated with a lower risk of cardiovascular events (CVEs).
Some background
Coronary artery disease (CAD) is caused by a reduced blood supply to the heart. Atherosclerotic disease (ASD) is a form of CAD. It is caused by a build-up of fatty deposits in the arteries. ASD can lead to cardiovascular events (CVEs). CVEs include heart attacks, stroke, and death. Coronary revascularization (CRV) can also occur leading to narrowing of blocked arteries.
The risk of CVEs can be reduced using lipid (fat) lowering drugs (LLDs). Alirocumab (Ali) and evolocumab (Evo) are LLDs. They block an enzyme called PCSK9. This enzyme is involved in the production of cholesterol. Cholesterol is a fat that contributes to CAD. Ali and Ebo are relatively new drugs. Most of the information has been obtained from clinical trials in specific populations. It is unclear if Ali and Eli are safe and effective in clinical practice.
Methods & findings
This study analyzed data from 39 clinical trials. 66,478 patients were included in this analysis. 35,896 of these patients were taking Ali or Evo. The authors analyzed the rates of CVEs. They compared the effects of Ali and Eli to other LLDs and placebo (inactive drug).
Ali was associated with a 19% lower risk of death compared to placebo. ALC and EVC were associated with a 20% lower risk of a heart attack. They were also associated with a 22% reduced stroke and a 17% lower risk of CRV.
Side effects were similar with Ali/Evo and other LLDs. There was a higher risk of injection site reactions in Ali/Evo-treated patients.
The bottom line
The authors concluded that Ali and Evo are associated with a lower risk of CVEs.
The fine print
This was a retrospective study, meaning it was based on medical records. As a result, it is unclear if Ali or Evo is more or less effective in certain patients.
What’s next?
If you have any concerns regarding CAD please discuss this with your doctor.
Published By :
European Heart Journal
Date :
Jul 03, 2019
